Latest Commercialization News

Aguia Resources is advancing steadily towards mining commencement at its Três Estradas phosphate project in Brazil, with key infrastructure completed and sales agreements signed for its PAMPAFOS™ fertilizer product.

West Coast Silver and Artemis Resources have signed a non-binding MOU to assess processing Elizabeth Hill silver ore at Artemis’s Radio Hill plant, aiming to fast-track development while managing capital costs.

Ariana Resources has successfully completed its first gold-silver doré pour at the Tavşan Mine in Türkiye, signaling the start of heap-leach production and a ramp-up toward steady-state output by mid-2026.

Argenica Therapeutics has demonstrated that its lead drug candidate ARG-007 does not interfere with the clot-busting agent tenecteplase, fulfilling a critical FDA requirement and advancing its stroke therapy development.

Mach7 Technologies has inked a five-year subscription agreement with UnityPoint Health, marking the first commercial deployment of its new Flamingo Architecture and setting the stage for significant recurring revenue growth.

Avecho Biotechnology has received patent allowances in the US and Europe for its proprietary CBD soft-gel formulation, reinforcing its intellectual property ahead of pivotal Phase III insomnia trial results expected in mid-2026.

Beetaloo Energy has secured crucial Federal Ministerial approval to sell appraisal gas from its EP187 exploration project, moving closer to final Northern Territory Government endorsement.

4DMedical has expanded its partnership with Philips, securing a US$10 million order commitment to distribute its CT – VQ™ lung imaging technology across North America, aiming to transform pulmonary diagnostics.

Vulcan Energy Resources has locked in full financing for its Phase One Lionheart project, marking a pivotal step toward producing carbon-neutral lithium hydroxide in Germany by 2028. The €2.2 billion package combines debt, equity, and government grants, underpinning robust project economics and strategic partnerships.

Talga Group has applied for a SEK 1.1 billion grant to fund a commercial-scale battery anode plant in Sweden, complementing existing EU funding and securing strong customer interest.

OncoSil Medical’s interim OSPREY registry data reveals promising survival improvements for patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ plus chemotherapy. The findings suggest a meaningful step forward in a field with limited effective options.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.